Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase...

by Zinzani Pier, Khuageva Nuriet K, Wang Huaqing, Garicochea Bernardo, Walewski Jan, Van Hoof Achiel, Soubeyran Pierre, Caballero Dolores, Buckstein Rena, Esseltine Dixie-Lee, Theocharous Panteli, Enny Christopher, Zhu Eugene, Elsayed Yusri A, Coiffier Bertrand
Published 2012-10-01